

Identify and Assess 2019 Novel Coronavirus (COVID-19)

For the evaluation of patients who may be ill with or who may have been exposed to COVID-19

Adapted from the Centers of Disease Control and Prevention, last updated February 28, 2020



Identify Patients at Risk

Exposure Risk	AND	Clinical Signs of Illness
Travel to China, Iran, Italy, Japan, South Korea, or close contact with person known to have COVID-19 illness within 14 days of symptom onset		Fever, cough, shortness of breath, symptoms of lower respiratory illness

If both exposure risk and clinical signs of illness are present



Isolate Patient

- Place face mask on patient
- Isolate patient in private room or a separate area
- Wear appropriate personal protective equipment

Assess Clinical Status

Physical Exam	Presence of Fever Subjective? Measured? ____ °C/°F	Presence of Respiratory Illness Cough? Shortness of breath?
----------------------	--	---

Inform Centers for Disease Control and Prevention

Contact health department to report at-risk patients and their clinical status	Assess need to collect specimens to test for COVID-19	Decide disposition
<p>Immediately contact CDC's Emergency Operations Center (EOC) at 770-488-7100 and complete a COVID-19 Person Under Investigation form available here: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html</p> <p>CDC's EOC will assist local/state health departments to collect, store, and ship specimens appropriately to CDC, including during afterhours or on weekends/holidays.</p>	<p>Collect two specimen types for PCR testing</p> <ul style="list-style-type: none"> - Upper respiratory specimen: nasopharyngeal AND oropharyngeal swab, nasopharyngeal wash/aspirate, or nasal aspirate AND - Lower respiratory specimen: bronchoalveolar lavage, tracheal aspirates, or sputum 	<p>Hospitalization needed?</p> <ul style="list-style-type: none"> - If yes, treat in an Airborne Infection Isolation Room (AIIR) - Use standard, contact, and airborne precautions with eye protection when treating patient - There are no FDA approved medications to treat COVID-19 currently. However, Remdesivir is an investigational antiviral drug that is being studied in two clinical trials in China for the treatment of severe or mild/moderate COVID-19. <p>Able to discharge home?</p>

If patient is to be discharged to home



Instruct

Instruct patient as needed depending on severity of illness and health department consultation:

- Home care guidance
- Home isolation guidance

Advise

Advise patient if new or worsening fever or respiratory illness develops:

- Call clinic to determine if reevaluation is needed
- If reevaluation needed, call ahead and wear facemask to clinic

References:

1. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/2019-nCoV-identify-assess-flowchart-508.pdf>
2. Information for Healthcare Professionals: COVID-19. (2020, February 27). Retrieved from <https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html>